These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 7641404

  • 1. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [Abstract] [Full Text] [Related]

  • 2. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU.
    Cancer; 1995 Aug 01; 76(3):479-89. PubMed ID: 8625130
    [Abstract] [Full Text] [Related]

  • 3. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
    Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF.
    Rev Med Chil; 2001 Jul 01; 129(7):713-8. PubMed ID: 11552438
    [Abstract] [Full Text] [Related]

  • 4. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J, Wallin G, Hamberger B, Nordenskjöld M, Weber G, Larsson C.
    Hum Mol Genet; 1994 Aug 01; 3(8):1259-62. PubMed ID: 7987299
    [Abstract] [Full Text] [Related]

  • 5. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995 Aug 01; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 6. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, Filetti S.
    J Endocrinol Invest; 1998 Jun 01; 21(6):358-64. PubMed ID: 9699127
    [Abstract] [Full Text] [Related]

  • 7. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M, Weinhüsel A, Niederle B, Haas OA.
    Int J Cancer; 1996 Aug 22; 69(4):312-6. PubMed ID: 8797874
    [Abstract] [Full Text] [Related]

  • 8. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
    Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y.
    J Hum Genet; 1998 Aug 22; 43(2):101-6. PubMed ID: 9621513
    [Abstract] [Full Text] [Related]

  • 9. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas.
    Scurini C, Quadro L, Fattoruso O, Verga U, Libroia A, Lupoli G, Cascone E, Marzano L, Paracchi S, Busnardo B, Girelli ME, Bellastella A, Colantuoni V.
    Mol Cell Endocrinol; 1998 Feb 22; 137(1):51-7. PubMed ID: 9607728
    [Abstract] [Full Text] [Related]

  • 10. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barontini M.
    Cancer; 2002 Jan 15; 94(2):323-30. PubMed ID: 11900218
    [Abstract] [Full Text] [Related]

  • 11. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
    Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L.
    Eur J Endocrinol; 1997 Apr 15; 136(4):423-6. PubMed ID: 9150704
    [Abstract] [Full Text] [Related]

  • 12. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A.
    J Clin Endocrinol Metab; 2007 Dec 15; 92(12):4725-9. PubMed ID: 17895320
    [Abstract] [Full Text] [Related]

  • 13. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
    González B, Salcedo M, Medrano ME, Mantilla A, Quiñónez G, Benítez-Bribiesca L, Rodríguez-Cuevas S, Cabrera L, de León B, Altamirano N, Tapia J, Dawson B.
    Arch Med Res; 2003 Dec 15; 34(1):41-9. PubMed ID: 12604374
    [Abstract] [Full Text] [Related]

  • 14. RET protooncogene mutations in patients with apparently sporadic medullary thyroid carcinoma.
    Huang CN, Wu SL, Chang TC, Huang SH, Chang TJ.
    J Formos Med Assoc; 1998 Aug 15; 97(8):541-6. PubMed ID: 9747064
    [Abstract] [Full Text] [Related]

  • 15. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
    Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T, Takahashi M.
    Jpn J Cancer Res; 1999 Nov 15; 90(11):1231-7. PubMed ID: 10622534
    [Abstract] [Full Text] [Related]

  • 16. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ, Mulligan LM, Eng C.
    Horm Res; 1997 Nov 15; 47(4-6):168-78. PubMed ID: 9167949
    [Abstract] [Full Text] [Related]

  • 17. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.
    Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF.
    J Clin Endocrinol Metab; 1996 Oct 15; 81(10):3740-5. PubMed ID: 8855832
    [Abstract] [Full Text] [Related]

  • 18. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma.
    Jindrichova S, Kodet R, Krskova L, Vlcek P, Bendlova B.
    J Mol Med (Berl); 2003 Dec 15; 81(12):819-23. PubMed ID: 14618242
    [Abstract] [Full Text] [Related]

  • 19. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Maeda S, Namba H, Takamura N, Tanigawa K, Takahashi M, Noguchi S, Nagataki S, Kanematsu T, Yamashita S.
    Endocr J; 1995 Apr 15; 42(2):245-50. PubMed ID: 7627269
    [Abstract] [Full Text] [Related]

  • 20. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.
    Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA.
    Oncogene; 1997 Jun 26; 14(25):3103-6. PubMed ID: 9223675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.